🔹 Revenue: $10.86B (Est. $10.69B) 🟢; UP +3% YoY
🔹 Organic Revenue Growth: +2% (Est. +0.8%) 🟢
🔹 Adj. EPS: $5.36 (Est. $5.24) 🟢
🔹 Adj. OI: $2.38B; UP from $2.35B YoY
Strategic & Product Highlights
🔹 Launched next-gen mass spectrometers: Orbitrap™ Astral™ Zoom, Excedion™ Pro, and Krios™ 5 Cryo-TEM
🔹 Expanded DynaDrive™ bioreactor portfolio with new bench-scale system
🔹 Accelerator™ Drug Development solution validated by Tufts Center study
🔹 Expanded U.S. sterile fill-finish capacity via Sanofi Ridgefield site acquisition
CEO Commentary
🔸 “Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment.”
🔸 “Trusted partner status and agility of our PPI Business System help us adapt, manage costs, and gain market share.”
🔸 “We’re on track to meet 2025 commitments and building a brighter future for Thermo Fisher.”
Outlook
🔸 Updated FY25 guidance to be provided during earnings call